Overview

Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This study aims to define a safe prophylactic intravenous TXA dose with an advantage over others in reducing total blood loss volume at secondary uncomplicated LSCS.
Phase:
Phase 4
Details
Lead Sponsor:
Talkha Central Hospital
Collaborator:
Al-Azhar University
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Pharmaceutical Solutions
Tranexamic Acid